Lenalidomide as second‐line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy

• Published in: Alimentary pharmacology & therapeutics Vol. 46; no. 8; pp. 722 - 730
• Main Authors: Shao, Y.‐Y., Chen, B.‐B., Ou, D.‐L., Lin, Z.‐Z., Hsu, C.‐H., Wang, M.‐J., Cheng, A.‐L., Hsu, C.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.10.2017
• Subjects: Adult; Aged; alpha-Fetoproteins - metabolism; Angiogenesis; Angiogenesis Inhibitors - therapeutic use; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Biomarkers; Biomarkers, Tumor - metabolism; Carcinoma, Hepatocellular - drug therapy; Disease control; Disease Progression; Disease-Free Survival; Female; Hepatocellular carcinoma; Humans; Immunomodulation; Immunotherapy; Liver cancer; Liver Neoplasms - drug therapy; Lymphocytes B; Magnetic resonance imaging; Male; Middle Aged; Niacinamide - administration & dosage; Niacinamide - analogs & derivatives; Peripheral blood; Phenylurea Compounds - administration & dosage; Survival; Targeted cancer therapy; Thalidomide - administration & dosage; Thalidomide - analogs & derivatives; Treatment Outcome; Tumors

Background Lenalidomide has immunomodulatory and anti‐angiogenic effects and showed moderate anti‐tumour efficacy in patients with. advanced hepatocellular carcinoma (HCC) Aim To explore potential biomarkers of lenalidomide efficacy as second‐line therapy for HCC. Methods Eligible patients were diag...